The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
Researchers found that telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The partners will exchange all information they have on genetic mutations leading to cancer with an eye toward accelerating research and drug discovery efforts.
The company's diagnostic is being used to determine the eligibility of patients with solid tumors to participate in a Phase II trial of entrectinib.
The hospitals plan to use the Watson technology to help their clinicians personalize cancer treatment options for their patients.
The investment, which will be paid out over the course of five years, comes in part from industry sources.
The system will immune-profile the phenotypic and functional endpoints of cells and secreted proteins from cancer patients in order to inform treatment decisions.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.